Rani Therapeutics Holdings, Inc.
RANI
$0.84
-$0.03-3.73%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 306.42% | 164.08% | 58.85% | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 306.42% | 164.08% | 58.85% | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 306.42% | 164.08% | 58.85% | -- | -- |
| SG&A Expenses | -10.03% | -17.76% | -17.57% | -17.27% | -14.28% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -19.09% | -22.50% | -21.11% | -18.48% | -19.16% |
| Operating Income | 27.66% | 27.20% | 22.76% | 20.80% | 21.24% |
| Income Before Tax | 36.22% | 33.58% | 27.63% | 13.33% | 13.42% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 36.22% | 33.58% | 27.63% | 13.33% | 13.42% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -85.55% | -72.58% | -57.55% | -27.91% | -24.13% |
| Net Income | -1.53% | 1.20% | 1.15% | -0.52% | 2.93% |
| EBIT | 27.66% | 27.20% | 22.76% | 20.80% | 21.24% |
| EBITDA | 27.63% | 27.33% | 22.98% | 21.19% | 21.71% |
| EPS Basic | 61.41% | 49.79% | 36.25% | 25.08% | 22.94% |
| Normalized Basic EPS | 16.20% | -2.98% | -25.02% | 23.27% | 22.94% |
| EPS Diluted | 61.41% | 49.79% | 36.25% | 25.08% | 22.94% |
| Normalized Diluted EPS | 16.20% | -2.98% | -25.02% | 23.27% | 22.94% |
| Average Basic Shares Outstanding | 264.89% | 171.42% | 60.35% | 39.24% | 26.68% |
| Average Diluted Shares Outstanding | 264.89% | 171.42% | 60.35% | 39.24% | 26.68% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |